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http://dx.doi.org/10.1016/j.ccr.2014.04.026SUMMARYB cells foster squamous cell carcinoma (SCC) development through deposition of immunoglobulin-contain-
ing immune complexes in premalignant tissue and Fcg receptor-dependent activation of myeloid cells.
Because human SCCs of the vulva and head and neck exhibited hallmarks of B cell infiltration, we examined
B cell-deficientmice and found reduced support for SCCgrowth. Although ineffective as a single agent, treat-
ment of mice bearing preexisting SCCs with B cell-depleting aCD20 monoclonal antibodies improved
response to platinum- and Taxol-based chemotherapy. Improved chemoresponsiveness was dependent
on altered chemokine expression by macrophages that promoted tumor infiltration of activated CD8+
lymphocytes via CCR5-dependent mechanisms. These data reveal that B cells, and the downstream
myeloid-based pathways they regulate, represent tractable targets for anticancer therapy in select tumors.INTRODUCTION
As the central component of humoral immunity, B lymphocytes
function in immunoglobulin (Ig) production, antigen presentation,
and secretion of proinflammatory cytokines. Although critical for
combating pathogens and aiding tissue healing, population-
based studies have revealed increased systemic humoral
immune responses, including increased deposition of Ig into
tissues, in individuals afflicted with some chronic inflammatorySignificance
The tumor immune microenvironment mediates all aspects of
for enhancing traditional and targeted anticancer therapies. He
man papillomaviruses (HPVs) as harboring immunoglobulin-pr
of HPV16-regulated SCC for efficacy of B cell depletion as mon
therapy. Administration of CD20 monoclonal antibodies signifi
expression of an altered repertoire of chemokines expressed
toxic T lymphocytes. These results indicate that the immune m
rammed to foster productive antitumor immune responses thadisorders associatedwith increased cancer risk. Cancer patients
often develop antibodies to tumor-associated antigens; how-
ever, production of these antibodies does not necessarily confer
protection, but instead often correlates with poor prognosis and
decreased survival for several human cancer types. Population-
based and experimental studies indicate that antitumor
antibodies can facilitate tumor growth by promoting protumor
immune responses and, in general, protecting malignant cells
from cytotoxic T cell (CTL)-mediated killing (Gunderson andcarcinogenesis, targeting of which is an attractive approach
rein, we identified human SCCs associated with high-risk hu-
oducing B cells. Based on this, we evaluated a murine model
otherapy, and in combination with standard-of-care chemo-
cantly improved response to chemotherapy dependent on
by macrophages, resulting in increased recruitment of cyto-
icroenvironment in susceptible solid tumors can be reprog-
t bolster response to cytotoxic therapy.
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B Cells as a Therapeutic Target in SCCCoussens, 2013; Tan and Coussens, 2007), thus supporting a
role for B cells and humoral immunity in fostering cancer
development. Support for a protumor role for B cells is further
provided by the realization that growth of some subcutaneous
solid tumors is retarded in syngeneic B cell-deficient mice, asso-
ciated with enhanced local expression of T helper (Th) 1 cyto-
kines and increased infiltration of tumors by CTLs (Qin et al.,
1998; Shah et al., 2005; Tadmor et al., 2011).
Using a transgenic mouse model of de novo squamous cell
carcinoma (SCC) development (Coussens et al., 1996), we
reported that B cells and humoral immunity foster SCC develop-
ment by activating Fcg receptors (FcgRs) on resident and
recruited myeloid cells (Andreu et al., 2010; de Visser et al.,
2005). Rather than infiltrating premalignant skin, Ig-secreting B
cells exert distal effects on neoplastic tissue via production of
circulating immune complexes (CICs) that accumulate in prema-
lignant tissue (Andreu et al., 2010; de Visser et al., 2005).
Following CIC engagement of activating-type I and activating-
type III FcgRs, tumor progression is fostered through activation
of proangiogenic, tissue remodeling, and prosurvival pathways
in resident and recruited myeloid cells, in particular, macro-
phages and mast cells (Andreu et al., 2010). Based on these
data, we hypothesized that B cells, and the downstream
myeloid-based pathways they regulate, represented tractable
targets for combinatorial therapy in SCC.We therefore examined
the preclinical efficacy of a B cell-depleting aCD20 monoclonal
antibody (mAb) as an anticancer monotherapy, and in combina-
tion with chemotherapy (CTX).
RESULTS
B Cells in Human Solid Tumors
Unlike squamous carcinoma development in mice wherein pre-
malignant and malignant tissues are poorly infiltrated by B cells
(Andreu et al., 2010; de Visser et al., 2005; Schioppa et al.,
2011), formation of tertiary/ectopic lymphoid structures contain-
ing B cells has been described for several human malignancies,
including breast, cervical, ovarian, and non-small-cell lung
cancer (Kobayashi et al., 2002; Nelson, 2010). Based upon these
data, we hypothesized that ectopic production of either Ig or
CD20 mRNA might signify human cancers wherein the humoral
immune response fosters neoplastic progression or tumor
growth, and thus identify carcinomas potentially amenable to B
cell-targeted therapies.
To address this, we queried cDNA microarray data on a panel
of human tumors from the BioExpress System and assessed
CD20 (MS4A1) and Ig (IGHG1, IGHG2, IGHV4-31, IGHM)
mRNA expression relative to corresponding normal tissue. Mul-
tiple tumor types displayed increased CD20 or Ig expression asFigure 1. CD20 and Ig mRNA Expression in Human Cancers
(A and B) Relative CD20 (A) and Ig (B) mRNA expression in a panel of human ca
change value compared to normal tissue, displaying the first and third quartiles
whiskers. Number of human cancer tissue/number of normal tissue is shown for e
cancer tissue and control normal tissue, with significance determined via Wilcox
(C) Representative histology of skin, vulva, and HNSCC in comparison to norma
immunohistochemistry (IHC) staining for CD45+ leukocytes and CD20+ B cells.
(D) Density of CD45+, CD20+, and CD8+ cells as determined by automated coun
See Figure S1 for complete analysis.compared to nonmalignant tissue counterparts, but vulva SCCs
and head and neck squamous cell carcinomas (HNSCCs) ex-
hibited the greatest increase in CD20 and Ig mRNA expression,
respectively (Figures 1A and 1B and Figure S1A available on-
line), consistent with increased presence of CD20+ B cells in
skin, vulva, and HNSCC as revealed by immunodetection (Fig-
ures 1C and 1D). Several Ig and FcR mRNAs were also found
to be differentially expressed in HNSCC tumors relative to
normal mucosa based on evaluation of a previously published
data set (Ginos et al., 2004) using Oncomine (Rhodes et al.,
2004) (Figure S1B). Notably, etiology for both vulva and
HNSCCs is in part linked to human papillomavirus (HPV), with
increasing incidence of carcinomas in both reflecting higher
rates of HPV infection (Chaturvedi, 2010; Chaturvedi et al.,
2011).
We have previously established that progression to carci-
noma in a murine model of HPV16-induced SCC development
(i.e., human keratin 14 [K14]-HPV16 mice) is dependent on
binding of Igs to activating FcgRs on infiltrating myeloid cells
(Andreu et al., 2010). Importantly, K14-HPV16 mice are not
tolerant to HPV oncoproteins (Andreu et al., 2010; Daniel
et al., 2005), reflecting a similar scenario in HPV-positive
oropharyngeal cancer wherein HPV-specific peripheral blood
CD8+ T cells have been described previously (Albers et al.,
2005; Wansom et al., 2010). We therefore sought to evaluate
the therapeutic efficacy of B cell depletion (i.e., aCD20
mAbs) or inhibition of Fcg signaling via a selective spleen
tyrosine kinase (Syk) inhibitor (i.e., fostamatinib/R788) (Brasel-
mann et al., 2006; Colonna et al., 2010) in either slowing
or blocking progression of premalignant hyperplasia to
dysplasia/carcinoma in situ.
Prevention of Premalignant Dysplasia by B Cell
Depletion or Syk Kinase Inhibition
B cells, including mature B cells and plasma cells, accumulate in
lymphoid organs of K14-HPV16 mice when neoplastic skin is at
an early premalignant stage (Figures S2A–S2G). Accordingly, we
conducted a prevention trial treating K14-HPV16 mice, starting
at 1 month of age, with aCD20 mAbs to effectively deplete B
cells, as well as with the potent Syk inhibitor fostamatinib/
R788, starting at 1 month of age, when neoplastic skin exhibited
a low-grade hyperplastic state throughout, and continuing to
4 months of age when neoplastic skin instead contained focal
areas of low/high-grade dysplasia (Figure 2A). R788 is an orally
bioavailable small molecule with potent Syk kinase inhibitory ac-
tivity, whose active metabolite (R406) binds the ATP binding
pocket of Syk and inhibits its kinase activity as an ATP-compet-
itive inhibitor (inhibitor constant [Ki] = 30 nM) (Bahjat et al., 2008;
Braselmann et al., 2006). Syk plays a key role in signalingncers. Data are represented as box-and-whisker plots depicting median fold
at the end of each box, with the maximum and minimum at the ends of the
ach organ. Shown are tissues with statistically significant differences between
on rank-sum test, with *p < 0.05, **p < 0.01, and ***p < 0.001.
l skin tissue. From left to right are hematoxylin and eosin staining (H&E) and
ting of IHC-stained sections. Ca, carcinoma.
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Figure 2. Inhibited Neoplastic Progression in K14-HPV16 Mice by Therapeutic aCD20 mAb or Fostamatinib
(A) Two stages of squamous carcinogenesis were evaluated: K14-HPV16 mice were enrolled at 1 month of age and received aCD20 or isotype control aRW at a
2-week interval until mice were 4 months of age (prevention), and B cell depletion or Syk inhibition was initiated at 3 months of age at a 2-week interval until mice
were 6 months of age (intervention). Fostamatinib (R788), an orally bioavailable Syk kinase inhibitor, was administered through chow ad libitum at 2.0 g/kg/day to
HPV16/FcRg+/ and HPV16/FcRg/ mice at 1 month of age as compared to mice receiving control chow until 4 months of age.
(B) Percentages of ear skin (area) exhibiting dysplasia by 4 or 6months of age following aCD20mAb or fostamatinib administration. Values represent percentages
of dysplastic lesions compared to whole ear skin per mouse with five to ten mice per experimental group. Results shown represent mean ± SEM. Representative
H&E sections from the aCD20 mAb intervention study are shown to the right. Scale bars, 50 mm.
(C) Percentages of CD45+ immune cells in single-cell suspensions of skin as assessed by flow cytometry. Results shown represent mean ± SEM.
(D) Immune cell lineage analysis by flow cytometry as percentages of total CD45+ leukocyte infiltrates in ear tissue.
(E) Angiogenic vasculature in skin of cohorts as evaluated by CD31/platelet endothelial cell adhesion molecule-1 IHC. Values represent average of five high-
power fields of view per mouse.
(F) Keratinocyte proliferation in skin of mice cohorts as assessed by automated counting of BrdU-positive keratinocytes per square millimeter of premalignant
tissue. Data reflect three or more mice per group; statistical significance was determined via an unpaired t test, with *p < 0.05, **p < 0.01, and ***p < 0.001.
See also Figure S2.
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in several other cell lineages where activation leads to phosphor-
ylation of Syk and signal transduction via activation of phospho-
lipase Cg and/or AKT. Notably, expression of mRNAs for both
Syk and Bruton’s tyrosine kinase (BTK), another key signaling
molecule downstream of FcRs and BCRs, was increased in812 Cancer Cell 25, 809–821, June 16, 2014 ª2014 Elsevier Inc.HNSCC tumors relative to normal mucosa (Figure S1B). Phos-
phorylated BTK was also prominent in HNSCC tissue sections
in CD20+ B cells and other stromal cells, as compared to normal
mucosa (Figure 1C).
Administration of aCD20 mAbs to K14-HPV16 mice, but not a
Ragweed-specific isotype control (aRW), effectively depleted B
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B Cells as a Therapeutic Target in SCCcells in peripheral blood and secondary lymphoid organs
(Figures S2H–S2L), including a partial depletion of CD19+
CD1dhiCD5+ B regulatory cells (Figure S2M), a subset of
CD23loCD21hi marginal zone B cells (Figure S4B) implicated in
repressing antitumor immunity in two-stage skin carcinogenesis
(Schioppa et al., 2011), and in suppressing lymphoma (Horikawa
et al., 2011). Critically, aCD20 mAb treatment reduced levels of
circulating IgG1 (Figure S2N) and presence of autoantibodies
against collagen I (Figure S2O); and consistent with a role of
CIC deposition in skin of fostering neoplastic progression via
FcgRs, treatment with either aCD20 mAb or fostamatinib effec-
tively blocked progression to dysplasia in the prevention trial
(Figure 2B).
Because Ig deposition into neoplastic skin of K14-HPV16mice
becomes pronounced between 2 and 3 months of age, we also
conducted an intervention trial where 3-month-old K14-HPV16
mice with high-grade hyperplasia/low-grade focal dysplasia
were treated with aCD20 mAbs to 6 months of age, when
neoplastic skin exhibited broadly dysplastic regions of focal
high-grade dysplasia/carcinoma in situ (Figure 2A). In this setting
aswell, B cell depletion via aCD20mAb asmonotherapy blocked
progression to dysplasia and significantly induced regression to
a hyperplastic phenotype (Figure 2B).
Impaired progression to dysplasia in both trials was associ-
ated with significantly reduced infiltration of neoplastic skin by
CD45+ leukocytes (Figure 2C), encompassing reduced recruit-
ment of CD11b+Gr1+F4/80CD11c immature myeloid cells,
mast cells, and Gr1+ cells, with increased infiltration by CD11b+
Gr1F4/80+CD11c macrophages, and T cells (Figure 2D; Fig-
ures S2P–S2S), similar to results reported for K14-HPV16/B
cell-deficient and K14-HPV16/FcRg-deficient mice (Andreu
et al., 2010). In addition to limiting mast cell infiltration, R406,
the active metabolite of fostamatinib, significantly reduced
release of interleukin-4 (IL-4), tumor necrosis factor a (TNF-a),
IL-23, IL-9, and transforming growth factor b (TGF-b) from IgG-
stimulated bone marrow-derived mast cells in ex vivo assays
(Figure S2T).
Moreover, similar to results reported for K14-HPV16/B cell-
deficient and K14-HPV16/FcRg-deficient mice (Andreu et al.,
2010), the reduced and altered infiltration by leukocytes in
aCD20 mAb- and fostamatinib-treated K14-HPV16 mice was
associated with decreased development of angiogenic vascula-
ture (Figure 2E) that translated into diminished keratinocyte
hyperproliferation (Figure 2F). Taken together, these data indi-
cate that B cell depletion and Syk kinase inhibitionmay represent
therapeutic opportunities for prevention and/or intervention in
K14-HPV16-positive squamous neoplasms.
B Cell-Deficient Mice Fail to Support Orthotopic SCC
Tumor Growth
Given the increased expression of Ig mRNA in human SCCs (Fig-
ure 1) and the efficacy of aCD20 mAb in restricting premalignant
progression in K14-HPV16 transgenic mice (Figure 2), we next
sought to evaluate the antitumor efficacy of B cell depletion as
either monotherapy or in combination with CTX. For this, we
used SCC cell lines derived from K14-HPV16 mice (Arbeit
et al., 1996) harboring de novo grade I well-differentiated
(WDSC1) or poorly differentiated SCCs (PDSC5 clone 6). Similar
to our results in syngeneic FcRg-deficient mice (Andreu et al.,2010), orthotopic SCC growth was significantly reduced in
syngeneic B cell-deficient (JH/) mice (Figures 3A and 3B),
characterized by increased presence of CD45+ leukocytes,
decreased bromodeoxyuridine (BrdU)-positive keratinocytes,
increased cleaved caspase-3-positive cells, and decreased
tumor vascularization, along with increased presence of CD8+
T cells (Figure S3A).
Neoadjuvant aCD20 mAb as Monotherapy and
in Combination with CTX
These findings provided a compelling rationale for assessing
aCD20 mAb in a therapeutic setting. Thus, we evaluated
aCD20 mAb for efficacy in blocking development of syngeneic
SCCs, as compared to slowing or inducing regression of pre-
existent syngeneic SCCs. Mice were administered aCD20
mAb either at the time of tumor cell implantation and again
at 2-week intervals (day 0; every 14 days), or instead when
orthotopic tumors reached 50 mm3 (day 12), and then every
14 days (Figure 3C). Using this strategy, CD19+B220+CD138
mature B cells were efficiently depleted from lymphoid organs
(spleen and bone marrow) (Figure S3B), culminating in reduced
presence of circulating IgG1 (Figure S3C). Whereas adminis-
tration of aCD20 mAb concurrent with SCC implantation sig-
nificantly slowed tumor growth to end-stage (Figure 3C;
Figure S3D), accompanied by reduced development of angio-
genic vasculature (Figure S3E), tumor growth was not signifi-
cantly slowed when aCD20 mAb therapy was initiated after
tumors were apparent (Figure 3C; Figures S3D and S3E),
despite a significantly increased percentage of CD8+ T cells
infiltrating tumors (Figure 3D; Figure S3E).
Based on the increased presence of CD8+ T cells in ortho-
topic SCCs of aCD20 mAb-treated mice, we reasoned that ef-
ficacy might be enhanced by combination treatment with CTX.
Indeed, treatment of mice bearing preexistent SCCs with
aCD20 mAb in combination with cisplatin (CDPP) resulted in
tumor regression in all animals (Figure S4A), as compared to
CDPP alone, which was without effect. However, mice treated
with aCD20/CDPP exhibited a 50% survival rate, likely due to
cumulative impairment of liver and renal function (Figure S4B),
a clinically relevant outcome as it mirrors CDPP-associated
renal toxicity in cancer patients administered concomitant
rituximab (aCD20 mAb). Due to its reduced nephrotoxicity,
we instead evaluated carboplatin (CBDCA) as an alternative
alkylating-type cytotoxic agent that also had no significant
effect on tumor growth alone, but significantly slowed tumor
growth when combined with aCD20 mAb throughout duration
of the CTX cycle (Figure 4A), without evidence of toxicity or
morbidity (Figure S4B), thus achieving a more favorable
outcome.
To determine whether enhanced response to CTX was
restricted to platinum-based agents, we next evaluated the
microtubule polymer stabilizer paclitaxel (PTX) in combination
with aCD20 mAb and similarly found significantly slowed SCC
growth during the treatment cycle (Figure 4B), associated with
decreased serum IgG1 (Figure S4C). Histological evaluation of
tumors from combinatorial-treated mice revealed reduced
malignant keratinocyte proliferation that was paralleled by
increased cell death (cleaved caspase-3 positivity; Figure 4C).
We also note a reduction in vascular density (CD31+ vessels;Cancer Cell 25, 809–821, June 16, 2014 ª2014 Elsevier Inc. 813
Figure 3. B Cell-Deficient Mice Limit SCC Tumor Growth
(A and B) Growth of (A) PDSC5 (clone 6; PDSC5.6) and (B) WDSC1 tumor cells injected orthotopically into syngeneic JH+/+ (red), JH+/ (blue), and JH/ (green)
mice. * denotes statistically significant differences in tumor growth between JH+/ and JH/mice. One of two representative experiments is shown and depicted
as mean ± SEM (R10 mice per group). Representative H&E sections are shown to the right. Scale bars, 50 mm.
(C) Growth of PDSC5.6-derived tumors in syngeneic mice treated with 2-week interval dosing of aCD20 (red) or aRW (blue) mAb either at the time of PDCS5.6
tumor cell inoculation (day 0), or alternatively in mice that received aCD20 mAb (green) following appearance of visible tumors (day 12). * indicates statistically
significant differences between tumor growth in mice receiving aCD20 at day 12 compared to aCD20 or aRW at day 0. One of two representative experiments is
shown depicted as mean ± SEM (R10 mice per group).
(D) Infiltration of CD8+ T lymphocytes within tumors from (C) as assessed by flow cytometry (left) and IHC (right). Unless otherwise indicated, statistical signif-
icance was determined via an unpaired t test, with *p < 0.05 and **p < 0.01.
See also Figure S3.
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leakage as measured by Evans blue assay (Figure S4D).
Given that aCD20 mAb improved responsiveness to PTX, we
assessed the durability of tumor repression after one cycle of
combined aCD20/PTX therapy and found that tumor regrowth
was apparent within 10 days following cessation of PTX (Fig-
ure 4D). Because resistance to cytotoxic agents represents a
major limitation of CTX, we evaluated a second cycle of
aCD20/PTX therapy and found that tumors again responded to
combined therapy, but again, that regrowth was evident
following cessation of CTX (Figure 4D).
T Cell Infiltration in aCD20/PTX-Treated Tumors
To identify cellular mechanisms underlying slowing of tumor
growth and increased efficacy of PTX in aCD20-treated mice,
we evaluated leukocyte complexity of orthotopic SCCs by flow
cytometry and found that SCCs responding to aCD20/PTX con-
tained significantly increased infiltrates of both CD4+ and CD8+
T cells, as compared to tumors that regained growth kinetics
following therapy cessation (Figure 4D). Increased CD8+ T cell
infiltration in responding tumors from aCD20/PTX-treated mice
was not unique to this experimental setting, as when we
analyzed neoplastic skin from 4-month-old K14-HPV16/B cell-
deficient, HK14-PV16/FcRg-deficient, and K14-HPV16 mice
enrolled in the intervention trial with aCD20 mAbs (Figure 1),
we similarly observed increased presence of CD8+ T cells across
all experimental groups as compared to controls (Figure 4E). To
reveal the functional significance of increased T cell infiltrates,814 Cancer Cell 25, 809–821, June 16, 2014 ª2014 Elsevier Inc.CD4+ and CD8+ T cells were individually depleted from SCC-
bearing aCD20/PTX-treated mice (Figure S5A), thus revealing
that improved PTX responses in aCD20 mAb-treated mice
were CD8+ T cell dependent (Figure 5A), but CD4+ T cell inde-
pendent (Figure S5B). Moreover, depletion of CD8+ T cells
reinstated the characteristic density of CD31+ vessels to growing
tumors (Figure S5C).
To reveal molecular mediators regulating productive CD8+
T cell activity, we evaluated cytokine mRNA expression in
SCCs of treated mice and found significantly increased levels
of interferon a (IFNa) and granzyme B (GzmB), molecules
involved in regulating CD8+ T cell activity (Figure 5B). In addition,
this analysis revealed increased expression of the angiostatic
molecules angiopoietin-1 (Ang1) and CXCL10, consistent with
reduced development of vasculature in tumors from aCD20/
PTX-treated mice (Figure 4C) and our previous results (Andreu
et al., 2010).
Given these findings, we examined whether the improved PTX
response was due to increased numbers of CD8+ T cells, or
instead to improved functionality of infiltrating CD8+ T cells, by
evaluating mRNA expression of SCC infiltrating CD8+ and
CD4+ T cells isolated by fluorescence-activated cell sorting
(FACS). Regardless of prior aCD20 treatment, T cells infiltrating
SCCs had unchanged surface expression of activation markers
CD69 and CD44 (Figure S5D), and they expressed similar levels
of Th1/Th2/Th17-effector cytokines (IL-2, IL-4, IL-5, IL-10, IL-13,
IL-17a, IL-17f, IFN-g, TNF-a) and functional indicators of CD8+
T cell killing capability (e.g., GzmA, GzmB, Prf1) (Figure S5E).
Figure 4. B Cell Depletion Sensitizes Established Tumors to Cytotoxic Agents
(A and B) Growth of PDSC5.6 SCCs in syngeneic mice receiving aCD20 or aRWmAbs at the time of visible tumor appearance (day 10), followed 3 weeks later by
administration of the platinum-containing chemotherapeutic agents (A) CBDCA (50 mg/kg; every 4 days3 three doses) (5–10 mice per group) or (B) PTX (12 mg/
kg; every 4 days 3 three doses), with ten or more mice per group. One of at least two representative experiments is shown and depicted as mean ± SEM.
* indicates statistically significant differences in tumor growth between aCD20 mAb/CTX, as compared to aCD20 mAb alone.
(C) Analysis of tissue sections from PDSC5.6 SCCs from (B): tumor cell proliferation, apoptosis, and vascular density by either automated quantitation of BrdU+,
caspase-3+ cells, or manual counting of CD31+ structures in five high-power fields of view per mouse.
(D) Growth of PDSC5.6 SCCs in mice receiving multiple cycles of therapy (as shown) (R17 mice per group). Results shown represent mean ± SEM. Presence of
CD8+ andCD4+ T cells in PDSC5.6-derived SCCs, determined by flow cytometry, as percent of total CD45+ leukocytes within tumors at day 43 (stasis) and day 49
(regrowth) shown graphically on right.
(E) Infiltration of CD8+ T lymphocytes into premalignant skin from 4-month-old K14-HPV16/B cell-deficient mice, K14-HPV16/FcRg-deficient mice, and
K14-HPV16 mice enrolled in the intervention trial with aCD20 mAbs as assessed by flow cytometry as a percentage of CD45+ cells (5–17 mice per group). Unless
otherwise indicated, statistical significance was determined via an unpaired t test, with *p < 0.05, **p < 0.01, and ***p < 0.001.
See also Figure S4.
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by our grouped analysis, these results suggested the improved
therapeutic response associated with aCD20/PTX combinedtherapy was due to reprogramming of the immunemicroenviron-
ment to favor either survival or infiltration of CD8+ T cells that in
turn enhanced tumor cell killing.Cancer Cell 25, 809–821, June 16, 2014 ª2014 Elsevier Inc. 815
Figure 5. Combination aCD20 mAb Plus CTX Inhibits SCC Tumor Growth by CD8+ T Cell-Dependent Mechanisms
(A) Tumor growth of PDSC5.6-derived SCCs in mice treated with aCD20 mAb, or aCD8 (clone YTS169.4; 500 mg)-depleting mAb, alone or in combination with
PTX, as depicted by treatment regimen. One of two representative experiments is shown and depicted as mean ± SEM. * indicates statistically significant
differences in tumor growth between aCD20/PTX-treated mice compared to mice receiving aCD20 mAb alone (5–10 mice per group).
(B) mRNA expression of PDSC5.6 SCCs from PBS-perfused aCD20/PTX-treated mice compared to mice receiving aRW/PTX at day 45 of treatment
regimen.
(legend continued on next page)
Cancer Cell
B Cells as a Therapeutic Target in SCC
816 Cancer Cell 25, 809–821, June 16, 2014 ª2014 Elsevier Inc.
Cancer Cell
B Cells as a Therapeutic Target in SCCMacrophage Programming Regulates CD8+ T Cell
Recruitment
Given our previous findings that macrophages are functionally
reprogrammed to favor a more Th1-type (classically activated
or ‘‘M1-type’’) inflammatory state in K14-HPV16 mice lacking
either B cells or FcgRs (Andreu et al., 2010), we postulated
that aCD20 mAb therapy was similarly reprogramming macro-
phages in SCCs of treated mice and that a macrophage-depen-
dent mechanism differentially regulated CD8+ T cell infiltration.
To investigate this hypothesis, we purified splenic CD8+ T cells
(Figure S5F) and evaluated their chemotactic response to
conditioned medium derived from FACS-sorted CD11b+
Ly6CLy6G-F4/80+MHCII+ macrophages isolated from SCCs
of aCD20/PTX versus aRW/PTX-treated mice (Figure S5G) and
revealed a significant increase in CD8+ T cell recruitment in
response to conditioned medium from aCD20/PTX-derived
macrophages (Figure 5C). mRNA expression analysis of
CD11b+Gr1CD11cF4/80+MHCII+ macrophages isolated
from SCCs of aCD20/PTX-treated versus control mice revealed
increased mRNA expression of several chemokines variably
implicated in leukocyte recruitment, including Ccl2, Ccl3, Ccl5,
Ccl7, and Ccl9 (Figure 5D), but no significant changes in other
genes associated with macrophage repolarization, including
Il1b, Il6, Il10, Il12a, Cd163,Msr1, Arg1, or Ym1 (data not shown).
Splenic CD8+ T cells expressed CCR5 (binds CCL3, CCL4, and
CCL5) and CXCR3 (binds CXCL10, CXCL11, and CXCL12) (Fig-
ure S5H), both of which have been linked to robust antitumor re-
sponses (Gonza´lez-Martı´n et al., 2011; Hong et al., 2011). Thus,
we evaluated the effect of CCR5 and CXCR3 blockade on CD8+
T cell chemotaxis ex vivo and found that an aCCR5-blocking
mAb alone abated CD8+ T cell chemotaxis to levels observed
with macrophages isolated from SCCs of control aRW/PTX-
treated mice (Figure 5E). Importantly, limiting in vivo tumor
infiltration of macrophages with a neutralizing mAb to colony-
stimulating factor 1 (aCSF1) (Figure S5I) blocked the combinato-
rial effect of aCD20/PTX treatment (Figure 5F) and restored the
density of CD31+ vessels in SCCs to characteristic levels (Fig-
ure S5J). The combinatorial effect of aCD20/PTX treatment
was similarly reversed by depletion of CD8+ T cells and also by
use of the CCR5 inhibitor maraviroc (Figure 5F), collectively indi-
cating that response to CTX in SCCs is regulated by CCR5-
positive CD8+ T cells responding to macrophages programmed
by humoral immunity (Figure 6). In support of a central role for
CCL5/CCR5 in mediating a cytotoxic T cell response in SCC(C) Ex vivo recruitment of purified splenic CD8+ T lymphocytes in response to co
(CD11b+Ly6CLy6GF4/80+MHCII+) isolated fromPDSC5.6 SCCs of aCD20/PTX
are representative of two independent experiments.
(D) Cytokine mRNA expression of FACS-sorted macrophages (CD11b+Ly6CL
versus aRW/PTX-treated mice at day 45 of treatment regimen. Inset shows repr
visualized by b-actin (green) and DAPI (red) staining. Data represent mean fold ch
group).
(E) Ex vivo chemotaxis of purified splenic CD8+ T lymphocytes in response
Ly6CLy6GF4/80+MHCII+) isolated from PDSC5.6 SCCs in aCD20/PTX- versu
antibodies against CCR5 (10 mg/ml) or CXCR3 (10 mg/ml). Samples were assayed
Data are displayed as mean ± SEM. Statistical significance for (B)–(E) was deter
(F) Relative orthotopic growth of PDSC5.6 SCCs in syngeneic mice following adm
(clone YTS169.4), aCSF1-neutralizingmAb (clone 5A1), or the CCR5 inhibitor mara
SEM. * indicates statistically significant differences in tumor growth between aCD
way ANOVA (more than eight mice per group).
See also Figure S5.patients, we found a significant correlation between expression
ofCCL5 and expression of PRF1,GZMA,GZMB, andCD69 (Fig-
ure S5K) in human HNSCC (Ginos et al., 2004).
DISCUSSION
Herein, we provide evidence that therapeutic strategies aimed at
depleting B cells and/or dampening humoral immunity represent
tractable targets for anticancer therapy in SCC. In preclinical
prevention and intervention trials, treatment of K14-HPV16
transgenic mice with B cell-depleting aCD20 mAbs or a Syk in-
hibitor as monotherapy prevented neoplastic progression to
the dysplastic/carcinoma in situ state. Although SCC growth
was significantly slowed in either B cell- or FcgR-deficient
mice (Andreu et al., 2010), treatment of syngeneic mice bearing
preexistent orthotopic SCCs was without consequence
following aCD20 mAb monotherapy. However, when aCD20
mAb was delivered in combination with CTX (CDPP, CBDCA,
and PTX), SCC growth was significantly slowed, accompanied
by reduced tumor vascular density and increased T cell infiltra-
tion, effects not achieved by administration of CTX alone.
Improved SCC response to CTX in aCD20 mAb-treated mice
was dependent on presence of ‘‘reprogrammed’’ macrophages
producing CCR5 ligands, because depletion of either macro-
phages or CD8+ T cells restored SCC growth kinetics and
vascular density to characteristic levels. Together, these data
indicate that myeloid-based pathways regulated by humoral
immunity limit SCC responses to CTX not only by fostering tumor
angiogenesis, but also by impairing CD8+ T cell infiltration into
tumors. Immune microenvironments in solid tumors can there-
fore be effectively reprogrammed to elicit productive antitumor
immune responses that bolster response to cytotoxic therapy,
provided that specific protumoral immune pathways can be
identified and therapeutically targeted.
Treatment of solid tumors with CTX, although often useful for
palliation or prolonging life in the setting of advanced disease,
remains limited, with survival benefit often measured in months
for some tumor types. Having an adjunctive therapeutic option
to reverse or minimize chemoresistance, or to provide additive
benefit through alternate mechanisms (immunomodulation),
represents an attractive therapeutic strategy. Recent approval
of ipilimumab, an anti-CTLA4 mAb for use in malignant
melanoma (Hodi et al., 2010), and sipileucil-T, a dendritic cell
vaccine that prolongs survival but not disease-free survival innditioned medium derived from FACS-sorted tumor-associated macrophages
versus aRW/PTX-treatedmice assessed using a Boyden chamber assay. Data
y6G-F4/80+MHCII+) isolated from PDSC5.6-derived SCCs from aCD20/PTX
esentative confocal microscopy showing morphology of sorted macrophages
ange ± SEM in expression compared to aRW/PTX treatment group (n = 8 per
to conditioned medium derived from FACS-sorted macrophages (CD11b+
s aRW/PTX-treated mice assessed in the presence or absence of blocking
in triplicates for each tested condition with pooled samples from ten tumors.
mined via an unpaired t test, with *p < 0.05, **p < 0.01, and ***p < 0.001.
inistration of PTX in mice pretreated with aCD20 mAb, aCD8-depleting mAb
viroc (CCR5i) as depicted by treatment regimen shown. Data represent mean ±
20/PTX-treated mice as compared to all other groups as determined by two-
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Figure 6. B Cell Depletion Repolarizes Tumor-Associated Macro-
phages in SCC
Cartoon showing a putative model for improved chemotherapeutic responses
in SCCs following B cell depletion. Left: during tumor development, autoan-
tibody production by B cells leads to deposition of immune complexes (IC)
within neoplastic tissue. Signaling of these complexes through activating FcgR
activates several protumor pathways, including angiogenic, tissue remodel-
ing, and prosurvival pathways in mast cells and Th2-tumor-associated mac-
rophages (TAMs). Right: aCD20 mAb therapy reduces presence of B cells and
Ig, the absence of which fosters development of TAMs that instead express
increased levels of angiostatic (CXCL10, 11), and CCR chemokines that
enhance CD8+ T cell infiltration of malignant tumors culminating in improved
response toCTX. Tumor growth to end-stage is thereby significantly slowed by
enhanced cytotoxic effects on tumor cells and indirectly through effects on
vasculature.
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B Cells as a Therapeutic Target in SCChormone-refractory prostate cancer (Kantoff et al., 2010; Small
et al., 2006), engenders not only support for immunotherapy in
general, but also the concept that immune responses to cancer
can be redirected for therapeutic gain. Although neither ipilimu-
mab nor sipileucil-T is currently approved for use in conjunction
with CTX, it is intriguing to speculate that their efficacy would be
improved if administered following CTX, or in combination with
therapies that blunt protumor immunity while also favoring an
antitumor immune microenvironment. Results presented herein
reveal that these types of responses can indeed be generated
by combining aCD20 mAb with CTX, similarly to that achieved
by delivery of CSF1 antagonists with CTX in mammary carci-
nomas (DeNardo et al., 2011). Although both modalities slow
tumor growth dependent on CD8+ T cells, these improvements
are achieved by distinct molecular mechanisms resulting from
lymphoid-based regulation of myeloid cell programming. These
distinctions may reflect organ-specific mechanisms governing
immune response, or nuances of the oncogenic drivers of solid
tumor development.
Clinically, vulva and oropharyngeal malignancies are typically
of a high-risk HPV viral etiology (Chaturvedi, 2010); thus, K14-
HPV16 mice phenocopy neoplastic progression in these tissues
and likely recapitulate a protumorigenic role for B cells and/or
humoral immunity in these locales. This assertion is consistent
with results from screening a diverse assortment of human solid818 Cancer Cell 25, 809–821, June 16, 2014 ª2014 Elsevier Inc.tumors for evidence of B cell infiltration, i.e., CD20 and/or Ig
mRNA expression, wherein vulva and HNSCCs contained signif-
icantly increased levels of CD20 and Ig mRNA, consistent with
histological evaluation of B cells in tumor tissue of these cancers
as well as in human cutaneous SCCs. Several other human
tumor types exhibited significant increases in CD20 and/or Ig
mRNA as compared to corresponding normal tissue. B cell-defi-
cient mice have previously been reported to also resist growth of
a range of syngeneic tumors, including thymoma, colon, and
mammary (Barbera-Guillem et al., 2000; Inoue et al., 2006;
Shah et al., 2005; Tadmor et al., 2011), but in most instances
these studies used nonorthotopic subcutaneous implantation.
In several of these models, the protumorigenic role of B cells
related to suppression of CD8+ T cell responses either directly
through IL-10 (Inoue et al., 2006; Schioppa et al., 2011; Wong
et al., 2010) or IL-15 (Chapoval et al., 1998), or indirectly through
TGF-b and generation of regulatory T cells (Olkhanud et al., 2011;
Tadmor et al., 2011). Whereas our previous findings indicated a
role for Igs and CICs in mediating these effects (Andreu et al.,
2010; de Visser et al., 2005), in other tumor models, adoptive
transfer of B lymphocytes, but not serum, restored tumor growth
accompanied by reduced Th1 cytokines and CTL responses,
suggestive of antibody-independent mechanisms (Ammirante
et al., 2010; Shah et al., 2005). Because B cells infiltrate human
SCCs, unlike what has been observed in murine models of
HPV16-induced SCCs (Andreu et al., 2010; de Visser et al.,
2005) and chemical carcinogenesis-induced SCCs (Schioppa
et al., 2011), we cannot rule out a potential role in human cancers
for other B/plasma cell-derived factors such as granulocyte-
macrophage-CSF (Rauch et al., 2012) or lymphotoxin (Moseman
et al., 2012), as has been described for growth of subcutaneous
androgen-independent metastatic prostate cancer cells (Ammir-
ante et al., 2010).
B cell depletion as an adjunct to CTX in solid tumors should be
relatively straightforward to address clinically. Rituximab is
already an approved drug for B cell malignancies (McLaughlin
et al., 1998), with no increased susceptibility to infection in
patients with adult acute lymphoblastic leukemia, rheumatoid
arthritis, or non-Hodgkin’s lymphoma (Silverman, 2006). This is
likely due to the fact that plasma cells are not depleted by
aCD20 mAb therapy. We observed ‘‘normalized’’ IgG levels in
tumor-bearing mice following aCD20 mAb therapy; thus, target-
ing pathological production of IgG through depletion of short-
lived autoreactive cells without affecting immunity derived from
plasma cells could be achieved in solid tumors, similar to that
described for arthritis (Huang et al., 2010) and peripheral nervous
system autoimmunity (Maurer et al., 2012). Although rituximab
has few cumulative side effects and has been combined safely
with many CTXs (Go¨kbuget and Hoelzer, 2006), it should be
noted that rituximab has been reported to increase risk of
some solid tumors in patients with lymphoma also treated with
high-dose CTX and stem cell autografts (Tarella et al., 2011).
Alternatively, the clinical success of ibrutinib, an irreversible
small-molecule inhibitor of BTK (expressed by both B cells and
myeloid cell subsets), engenders support for the notion that
targeting protumoral B cells and humoral immune-activated
pathways may improve overall survival in patients with tumors
regulated by these pathways, when administered in combination
with standard-of-care CTX.
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B Cells as a Therapeutic Target in SCCAlthough studies presented herein identify SCCs as potentially
benefiting from aCD20 mAb/CTX, the clinical relevance of
aCD20 mAb may not be limited to just these solid tumors.
Growth of experimental lung adenocarcinoma is reduced in B
cell-deficient mice, with an improved CTX response observed
upon coadministration with IL-15, a Th1 cytokine with IL-2-like
antitumor bioactivities (Chapoval et al., 1998). Moreover, in a
mouse model of melanoma, B cell deficiency provided a thera-
peutic advantage to amelanoma vaccinewhere enhanced tumor
protection in the absence of B cells was associated with
increased magnitude and longevity of specific cellular immune
responses provoked by vaccination (Perricone et al., 2004). We
also observed a striking increase in Ig expression in human
pancreatic ductal adenocarcinoma samples and are currently
evaluating whether this signature translates into a functional
role inmurine pancreas cancermodels. Notably, a limited clinical
study of advanced colon cancer patients treated with rituximab
resulted in reduced numbers of CD21-hyperpositive lympho-
cytes associated with apparent 50% reduction in tumor burden
with no ill effects due to therapy (Barbera-Guillem et al., 2000).
Because human SCCs appear to be enriched with tumor pro-
moting B cells, we propose these as tractable cancers in which
to examine efficacy of aCD20 mAb, or other antagonists block-
ing protumoral B cell/humoral immunity programs, such as Syk
or BTK inhibitors, in combination with CTX.
EXPERIMENTAL PROCEDURES
Microarray Data Normalization and Integration
Microarray data reflecting CD20 and Ig mRNA in human tumor samples were
queried from a commercially available data set (BioExpress System, Gene
Logic) originally generated on the Human Genome U133 Plus 2.0 Array (Affy-
metrix) and normalized by standard robust multichip average procedure. A
single probe set of the highest variance among samples was chosen to repre-
sent CD20 (228592_at; MS4A1) and Ig (211430_s_at; IGHG1, IGHG2, IGHV4-
31, IGHM), respectively. To ensure data consistency, results from additional
probe sets were compared to a single probe set. Median value was used to
calculate fold change of expression in tumor tissue compared to normal tissue.
Statistical analyses were performed usingWilcoxon rank-sum test to compare
mRNA expression levels to their corresponding normal tissue controls.
Immunohistochemistry
Staining on human tissue sections was performed as described previously
(Ruffell et al., 2012). De-identified human tissue was received from the Univer-
sity of California, San Francisco (UCSF) Department of Pathology under
approval from the UCSF Committee on Human Research (05028310), and
theOregon Health and Science University (OHSU) Department of Dermatology
Molecular Profiling Resource (institutional review board [IRB] #809), with
patient consent forms obtained at the time of tissue acquisition. The use of
samples occurred under ‘‘exempt category 4’’ for individuals receiving
de-identified biological specimens.
Animal Husbandry and In Vivo Studies
Generation and characterization of K14-HPV16 and JH/ mice have been
described previously (Andreu et al., 2010). Briefly, K14-HPV16 transgenic
mice represent a well-characterizedmodel of multistage epithelial carcinogen-
esis where HPV16 early region genes are expressed under control of a K14
promoter, i.e., K14-HPV16 mice (Arbeit et al., 1994; Coussens et al., 1996,
1999,2000; Daniel et al., 2003; de Visser et al., 2004, 2005; Rhee et al.,
2004; van Kempen et al., 2002). By 1 month of age, K14-HPV16 mice develop
hyperproliferative lesions (hyperplasias) throughout skin. Between 3 and
6 months of age, these hyperplasias progress into 100% penetrant focal dys-
plasias and are predisposed to progress intomultiple histologic grades of SCC
in50%ofmice on the FVB/n strain background, 30%ofwhichmetastasize toregional lymph nodes. Angiogenic vasculature is first evident in hyperplasias,
development of which is linked to infiltration of innate immune cells (de Visser
et al., 2004, 2005; van Kempen et al., 2002). All experiments with mice com-
plied with National Institutes of Health guidelines and were approved by the
UCSF Institutional Animal Care and Use Committee.
aCD20 mAB (clone 5D2, provided by Genentech) was generated by immu-
nizing CD20-deficient mice with a murine pre-B cell line (300.19) transfected
with murine CD20. cDNAs encoding heavy and light chain were cloned from
hybridomas and further used for transfection and antibody production in
Chinese hamster ovary cells. Ragweed-specific mouse IgG2a (aRW mAb)
was used as an isotype control. K14-HPV16 mice received aCD20 (200 mg)
or aRW (200 mg) mAb intraperitoneally (i.p.) at 2-week intervals commencing
at 1 or 3 months of age. Mice bearing syngeneic orthotopic tumors received
aCD20mAb (200 mg) or aRWmAb (200 mg) either at the time of tumor cell inoc-
ulation (day 0) or following appearance of palpable transplantable tumors
(e.g., day 12) at 2-week intervals for a total of three treatments. K14-HPV16/
FcRg+/ (R18 mice per cohort) and K14-HPV16/FcRg/ (R10 mice per
cohort) mice were fed chow containing orally soluble fostamatinib (R788) at
2.0 g of fostamatinib per kg of chow, as compared to control chow (AIN-
76A) (Rigel Pharmaceuticals) ad libitum beginning at 1 month of age and
continuing for a total of 12 weeks. Formulated chow was prepared by
Research Diets. R406 (R940406) is the active metabolite of fostamatinib
that acts as an ATP-competitive inhibitor (Ki = 30 nM), thus selectively inhibit-
ing Syk kinase activity as assessed using a large panel of Syk-dependent
and -independent cell-based assays (Braselmann et al., 2006). Plasma
R406 levels were monitored for 48, 51, 54, 57, and 58 hr, revealing peak
plasma levels at 558 ng/ml in male FVB/n mice and peak levels in female
FVB/n mice at 118.9 ng/ml (data not shown). Thus, using 2.0 mg/ml (10-fold
higher than the tested dose), Syk kinase activity in female FVB/n mice was
inhibited in vivo and was monitored as a function of plasma R406 levels and
Syk kinase activity in peripheral blood leukocytes.
Orthotopic Tumor Transplantation
PDSC5 and WDSC cells (0.5 3 106 cells) were suspended in 100 ml of base-
ment membrane extract Matrigel (BD Pharmingen) in PBS (1:1) and inoculated
orthotopically into back skin of 7-week-old female FVB/n mice. Transplantable
tumors were measured at 2-day intervals using a digital caliper, and tumor
volume was calculated using the equation V (mm3) = a 3 b2/2, where a is
largest diameter and b is smallest diameter. To assess effects of PTX
(12 mg/kg; Novaplus), CDPP (10 mg/ kg; Hospira), and CBDCA (50 mg/ kg;
APP Pharmaceuticals) on tumor growth, tumor-bearing mice were pretreated
with aCD20 mAb or aRWmAb as described above. Chemotherapeutic agents
were injected intravenously at 4-day intervals 1 week following administration
of the second dose of aCD20 or aRWmAb for a total of three treatments. Mice
were sacrificed 4 days following the last chemotherapeutic dose. For tumor
regression studies, mice were treated with aCD20 mAb/PTX following re-
growth of transplantable tumors. Mice received PTX at a 4-day interval for a
total of three treatments. For in vivo depletion studies, aCD4 (GK1.5) and
aCD8 (YTS169.4) mAbs were administered i.p. at 500 mg on day 4 following
initial treatment with aCD20 mAb at a 5-day interval, whereas aCSF1 (5A1) an-
tibodies (all from Bio X Cell) were administered i.p. at 1,000 mg 4 days prior to
the first chemotherapeutic dose, with subsequent doses of 500 mg every
4 days. Clinical grade maraviroc was dissolved at 300 mg/l in drinking water
for ad libitum dosing (Ochoa-Callejero et al., 2013).
Statistical Analyses
Statistical analyses were performed using Prism version 4 and/or InStat
version 3.0a for Macintosh (both GraphPad). Specific tests included Mann-
Whitney (unpaired, nonparametric, two-tailed), unpaired t test, and Wilcoxon
rank-sum and are identified in the respective figures. p Values < 0.05 were
considered statistically significant, with *p < 0.05, **p < 0.01, and ***p <
0.001 unless otherwise indicated.
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